Dr. Mervyn Turner, Ph.D.
Merv worked as an academic research scientist in the UK until joining Merck & Co. Inc. in New Jersey, with whom he worked for 26 years. He headed research at Merck’s largest site in New Jersey for six years, ran the research site in Montreal for three years, was head of World Wide Licensing and External Research for seven years, and finished his career as the company’s first Chief Strategy Officer. Since his retirement from Merck in 2011, Merv has operated his own consulting business. In addition to his role with EnGeneIC, he acts as an Advisor to Bay City Capital in San Francisco, serves on the Wellcome Trust’s “Seeding Drug Discovery Initiative” oversight committee in the UK, and sits on the Board of Preventice, a remote patient care/remote patient monitoring company based in Minneapolis.